Rocket Pharma ex-officer to sell 8,923 shares

Former officer John Militello files a Rule 144 notice to sell 8,923 RCKT shares from recent restricted stock vesting, partly to satisfy tax obligations.

Available on EDGAR 09/11/2026 - 04:55 PM EDT Accepted by SEC EDGAR 09/11/2026 - 04:55 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. (RCKT) is the issuer in a notice that former officer John Militello intends to sell common stock under Rule 144. The notice covers a proposed sale of 8,923 shares, acquired through restricted stock vesting on September 9, 2026, with part of the sale intended to cover related tax obligations. The filing also reports a prior sale of 1,252 shares of common stock on August 18, 2026.

Key Figures

Shares proposed for sale: 8,923 shares Aggregate market value of proposed sale: $30,367.65 Shares sold in prior 3 months: 1,252 shares +3 more

6 metrics

Shares proposed for sale 8,923 shares Common stock covered by the Rule 144 notice related to restricted stock vesting on September 9, 2026

Aggregate market value of proposed sale $30,367.65 Reported in the securities information section for the 8,923 shares of common stock

Shares sold in prior 3 months 1,252 shares Common stock sold on August 18, 2026, during the past three months

Aggregate value of prior sale $4,233.51 Value of the 1,252 RCKT shares sold on August 18, 2026

Date of restricted stock vesting September 9, 2026 Acquisition date of the 8,923 shares to be sold, described as Restricted Stock Vesting

Date of Rule 144 notice September 11, 2026 Date the notice of proposed sale was signed and filed

Key Terms

Rule 144, Restricted Stock Vesting, vested equity award

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 09/09/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

vested equity award financial

"resulting from the settlement of a vested equity award distribution."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for ROCKET PHARMACEUTICALS, INC. (RCKT)?

It discloses that former officer John Militello intends to sell 8,923 shares of RCKT common stock under Rule 144, received from restricted stock vesting on September 9, 2026, with part of the sale covering tax obligations from the vested equity award.

How many RCKT shares does John Militello plan to sell under this Form 144?

The notice covers a proposed sale of 8,923 shares of ROCKET PHARMACEUTICALS, INC. common stock. These shares were acquired through restricted stock vesting on September 9, 2026, and include an amount intended to cover a related tax obligation.

What prior RCKT share sales by John Militello are reported in the last three months?

The filing reports that on August 18, 2026, John Militello sold 1,252 shares of RCKT common stock for an aggregate value of $4,233.51 during the prior three months.

What is the stated reason for part of the planned RCKT share sale?

The remarks state that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution, indicating tax-related liquidity needs tied to the restricted stock vesting on September 9, 2026.

On which market are the RCKT shares involved in this Form 144 listed?

The common stock referenced in the Form 144 for ROCKET PHARMACEUTICALS, INC. is identified as being listed on NASDAQ, as indicated in the securities information section of the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001662170
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROCKET PHARMACEUTICALS, INC.
SEC File Number	001-36829
Address of Issuer	350 FIFTH AVENUE SUITE 7530 NEW YORK NEW YORK 10118
Phone	646-440-9100
Name of Person for Whose Account the Securities are To Be Sold	Militello John
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	8923	30367.65	109774597	09/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/09/2026	Restricted Stock Vesting	Issuer			8923	09/09/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John Militello 9 Cedarbrook Drive Cranbury NJ 08512	Common	08/18/2026	1252	4233.51

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	09/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for John Militello.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)